Keyphrases
Diabetes
100%
Intervention Studies
100%
Cardiovascular Disease
100%
Subgroup Analysis
100%
Department of Veterans Affairs
100%
Gemfibrozil
100%
High-density Lipoprotein Cholesterol (HDL-C)
100%
Plasma Insulin
100%
Fasting Insulin
60%
Confidence Interval
60%
Hazard Ratio
60%
Coronary Artery Disease
40%
Impaired Fasting Glucose
40%
Patients with Diabetes
40%
Fasting Plasma Glucose
40%
Coronary Heart Disease Mortality
40%
Glucose Level
40%
Without Diabetes
40%
Composite Endpoint
40%
Myocardial Infarction
20%
Type 1 Diabetes Mellitus (T1DM)
20%
Major Adverse Cardiovascular Events
20%
Risk Reduction
20%
Insulin Resistance
20%
Placebo
20%
Randomized Controlled Trial
20%
Cardiovascular Outcomes
20%
Cardiovascular Risk
20%
Glucose-insulin System
20%
Non-diabetic
20%
Low-density Lipoprotein Cholesterol (LDL-C)
20%
Glucose Tolerance
20%
Diabetes Status
20%
New-onset Diabetes
20%
Hyperinsulinemia
20%
Insulin Level
20%
Diabetes Risk Reduction
20%
Low-density Lipoprotein Cholesterol Level
20%
Medicine and Dentistry
Diabetes
100%
Cardiovascular Disease
100%
Subgroup Analysis
100%
Veterans Affairs
100%
High-Density Lipoprotein
100%
Intervention Trial
100%
Gemfibrozil
62%
Ischemic Heart Disease
50%
Hazard Ratio
37%
Cardiovascular System
25%
Risk Reduction
25%
High Density Lipoprotein Cholesterol
25%
Apoplexy
12%
Insulin Resistance
12%
Randomized Controlled Trial
12%
Myocardial Infarction
12%
Diabetes Mellitus
12%
Hyperinsulinemia
12%
Low Density Lipoprotein Cholesterol
12%
Impaired Fasting Glucose
12%
Glucose Tolerance
12%
Placebo
12%
Nursing and Health Professions
Insulin Blood Level
100%
High Density Lipoprotein
100%
Cardiovascular Disease
100%
Gemfibrozil
100%
Ischemic Heart Disease
80%
Hazard Ratio
60%
Glucose Level
60%
Confidence Interval
60%
High Density Lipoprotein Cholesterol Level
40%
Cerebrovascular Accident
20%
Heart Infarction
20%
Insulin Level
20%
Low Density Lipoprotein Cholesterol Level
20%
Placebo
20%
Glucose Tolerance
20%
Diabetes Mellitus
20%
Insulin Resistance
20%
Hyperinsulinemia
20%
Efficacy
20%